J&J Backs Off 340B Rebate Policy, Evades Sanctions And Ejection From Program

Johnson & Johnson informed HHS Monday (Sept. 30) it will put on hold its controversial new policy to start using rebates instead of up-front discounts for 340B drugs it supplies to disproportionate share hospitals, a J&J spokesman told Inside Drug Pricing , coming after HHS’ Health Resources and Services Administration (HRSA) on Friday threatened to kick J&J out of the 340B drug discount program unless it backed off the rebate policy by today. The spokesperson said the drug company hopes...